TherapeuticsMD, Inc. (NASDAQ: TXMD) reported its financial results for the first quarter ended March 31, 2025. The company disclosed a net loss from continuing operations of $636 thousand, or $(0.06) per basic and diluted common share, marking a decrease of $99 thousand compared to a net loss of $809 thousand, or $(0.07) per share, for the same period in 2024. License revenues from continuing operations, primarily derived from the Mayne License Agreement, increased by 25.8% to $393 thousand, up from $313 thousand in the first quarter of 2024. This increase was mainly due to changes in sales of licensed products. Total operating expenses also decreased by 13.1% to $1,264 thousand, attributed to efficiencies gained as a royalty-based business. Additionally, TherapeuticsMD is exploring various strategic alternatives, including potential acquisitions, mergers, or asset sales, although no specific outcome or timeline has been established. As of March 31, 2025, the company's cash and cash equivalents stood at $5.7 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.